J Psychiatry Neurosci 2020;45(4):229-233 | PDF
Rejish K. Thomas, MD, MSc; Raheem Suleman, MD, MSc; Marnie Mackay, PhD; Lovneet Hayer, MD; Mohit Singh, MD; Christoph U. Correll, MD; Serdar Dursun, MD, PhD
Affiliations: From the Nuns Community Hospital, Department of Psychiatry, Edmonton, Alta., Canada (Thomas, Dursun); the Department of Psychiatry, University of Alberta, Edmonton, Alta., Canada (Thomas, Dursun, Suleman, Mackay, Hayer, Singh); the Department of Telepsychiatry, Alberta Health Services, Edmonton, Alta., Canada (Thomas, Hayer, Singh); the Neurochemical Research Unit and Bebensee Schizophrenia Research Unit, Edmonton, Alta., Canada (Mackay); the Recognition and Prevention Program, Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll); the Department of Psychiatry and Molecular Medicine, Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA (Correll); and the Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany (Correll).
Competing interests: R. Thomas participates on advisory boards for Sunovion and Janssen and has received speaker fees from Sunovion, Janssen, Lundbeck and Otsuka. C. Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on data safety monitoring boards for Lundbeck, Rovi, Supernus and Teva. He received grant support from the Berlin Institute of health (BIH), Janssen, the National Institute of Mental Health (NIMH), Patient Centered Outcomes Research Institute (PCORI), Takeda and the Thrasher Foundation. He has received royalties from UpToDate and is also a stock option holder of LB Pharma. S. Dursun has previously acted on scientific advisory boards for Janssen Pharmaceuticals. No other competing interests were declared.
Correspondence to: R. Thomas, 11 Youville Dr NW, Room 1801, Edmonton, AB T6L 5X8; firstname.lastname@example.org